Denosumab As a Potential Therapeutic Option for Leiomyosarcoma with Osteoclast-like Giant Cells: A Case Report
Overview
Authors
Affiliations
Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.
Leiomyosarcoma with osteoclast-like (LMS-OGC) giant cells the breast: A report of a rare case.
Xu Z, Gu J, Zhang S, Zhang Z, Fang W Thorac Cancer. 2019; 10(10):2054-2056.
PMID: 31474003 PMC: 6775023. DOI: 10.1111/1759-7714.13190.